Allworth Financial
RXRX icon

Allworth Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Allworth Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69K Sell
1,822
-2,994
-62% -$9.97K ﹤0.01% 3970
2026
Q1 		$14.8K Buy
4,816
+913
+23% +$3.53K ﹤0.01% 3206
2025
Q4 		$16K Sell
3,903
-5,645
-59% -$28K ﹤0.01% 2953
2025
Q3 		$46.6K Buy
9,548
+4,403
+86% +$23.1K ﹤0.01% 2139
2025
Q2 		$26K Buy
5,145
+1,221
+31% +$6K ﹤0.01% 2355
2025
Q1 		$22.6K Buy
3,924
+2,529
+181% +$18.4K ﹤0.01% 2006
2024
Q4 		$10.4K Buy
1,395
+1,329
+2,014% +$8.94K ﹤0.01% 2420
2024
Q3 		$435 Buy
66
+5
+8% +$36 ﹤0.01% 3448
2024
Q2 		$465 Buy
61
+26
+74% +$227 ﹤0.01% 3388
2024
Q1 		$349 Hold
35
– – ﹤0.01% 3372
2023
Q4 		$346 Sell
35
-15
-30% -$107 ﹤0.01% 3208
2023
Q3 		$383 Buy
50
+15
+43% +$150 ﹤0.01% 3104
2023
Q2 		$262 Buy
+35
New +$245 ﹤0.01% 3045

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Allworth Financial's RXRX Position: Q2 2026 in Review

Allworth Financial reduced its Recursion Pharmaceuticals (RXRX) stake by 62% in Q2 2026, selling an estimated $9.97K and leaving 1,822 shares worth $6.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3970.

Allworth Financial first reported a position in RXRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $46.6K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Allworth Financial held 1,822 shares of Recursion Pharmaceuticals worth $6.69K as of Q2 2026.
  • Allworth Financial sold 2,994 Recursion Pharmaceuticals shares in Q2 2026, an estimated $9.97K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3970 holding.
  • Allworth Financial first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Allworth Financial's Recursion Pharmaceuticals position peaked at $46.6K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.